WHAT THE STUDY ACTUALLY SAYSIn a 74-patient phase 1/2 study, venetoclax-based therapy plus the FLT3 inhibitor quizartinib produced remissions in about half of older adults unfit for chemo, and more in the FLT3-mutated subgroup.
3 min read
WHAT THE STUDY ACTUALLY SAYSIn 120 older adults with acute myeloid leukaemia, adding midostaurin to two-drug therapy did not raise remission rates overall (72% vs 68%), but a small FLT3-mutated subgroup lived longer.
3 min read
THE DRUG DOCKETIn 709 children with high-risk B-cell ALL, swapping two chemotherapy cycles for the T-cell-engaging antibody lifted four-year event-free survival to 83% from 70% and sharply cut serious infections.
3 min read
WHAT THE STUDY ACTUALLY SAYSIn the 172-patient PARADIGM trial, azacitidine plus venetoclax more than doubled median event-free survival versus induction chemotherapy — but it was a phase 2 study not powered for overall survival.
3 min read
WHAT THE STUDY ACTUALLY SAYSIn the phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to a fixed course of venetoclax and rituximab raised 24-month progression-free survival to 87% from 72% in previously treated disease.
4 min read